
TMO Stock Forecast & Price Target
TMO Analyst Ratings
Bulls say
Thermo Fisher Scientific is well positioned because its 3Q organic revenue growth of 6% exceeded expectations, driven by strong momentum in Lab Products and Biopharma Services, where Pharma Services grew in the mid-to-high teens, and by Analytical Instruments’ 6% organic growth. Management raised FY26 revenue guidance to $47.7–48.2B and EPS to $25.13–25.43 while keeping about 4% organic growth intact, suggesting confidence that demand is improving rather than merely benefiting from timing. The company also showed resilient end-market breadth, with pharma and biotech, industrial and applied, and China improving, while margin expansion to 24.5% underscores operating leverage and a high-quality earnings profile.
Bears say
Thermo Fisher Scientific is viewed negatively because end-market demand normalization in scientific lab supply has taken years to materialize and may continue to disappoint after many false starts. Its growth profile also looks challenged, with 2026 organic sales guidance of about 3%-4% well below the long-term 7% target, while a large M&A platform may no longer earn the same valuation premium as scarce targets and pharma services expansion replace earlier consolidation wins. AI adds another overhang, since clinical research is about 20% of sales and core scientific research supply about 40%, both exposed to automation and wet-lab substitution concerns that could pressure growth and multiple support.
This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.
TMO Analyst Forecast & Price Prediction
Start investing in TMO
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Thermo Fisher Scientific (TMO) Forecast
TMO Analyst Forecast & Price Prediction
Start investing in TMO
Order type
Buy in
Order amount
Est. shares
0 shares